The inhibition of UPR pathways (PERK, IRE1α and ATF6 pathway) suppresses hepatic lipogenesis and insulin resistance, leading to the remission of NAFLD-related phenotypes (Fig. 6G). The gene discussed is ATF6; the disease is metabolic dysfunction-associated steatotic liver disease.